Kia Motors Corp. will decide next week when to resume operations in its two plants in Gwangmyeong, based on the development of COVID-19 cases over the weekend.
Quarantine officials are conducting tests on 151 people who had close contact with the confirmed patients.
There were 13 coronavirus cases traced to the plants, including four family members of the workers.
he automaker halted their operations late Wednesday following the confirmation of COVID-19 cases there days earlier.
The two plants in Gwangmyeong have a combined 6,000 workers and a combined annual capacity of 320,000.
The suspensions are feared to gravely impact production at Kia, which manufactures the K9 sedan, Stinger sports car, and Carnival minivan at one plant in Gwangmyeong, and the Pride subcompact and the Stonic subcompact SUV in the other plant.
Kia operates eight plants in South Korea and seven overseas ones that have a combined capacity of 3.84 million units.


TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core
One Percent Rule Checklist For Safer Forex Trading Risk
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 



